miR-107 regulates cisplatin chemosensitivity of A549 non small cell lung cancer cell line by targeting cyclin dependent kinase 8.

In conclusion, the present study provides the first evidence that miR-107 plays a key role in cisplatin resistance by targeting the CDK8 protein in NSCLC cell lines, suggesting that miR-107 can be used to predict a patient's response to chemotherapy as well as serve as a novel potential maker for NSCLC therapy.
PMID: 25400821 [PubMed - in process]

Source: Clinical Lung Cancer - November 19, 2014 Category: Cancer & Oncology Authors: Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B, Wang LQ, Zhang D Tags: Int J Clin Exp Pathol Source Type: research